Renal protective effect of chronic inhibition of COX-2 with SC-58236 in streptozotocin-diabetic rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 6, 2011, Pages

  Quilley, J ^a   Santos, M ^a   Pedraza, P ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Cyclooxygenase 2 inhibition; Kidney

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ADVANCED GLYCATION END PRODUCT; ALBUMIN; CYCLOOXYGENASE 2; GLUCOSE; PROSTAGLANDIN E2; THROMBOXANE; THROMBOXANE B2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; GLUCOSE BLOOD LEVEL; KIDNEY HYPERTROPHY; KIDNEY MASS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; STREPTOZOCIN DIABETES; TREATMENT DURATION; URINARY EXCRETION;

ALBUMINURIA; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CYCLOOXYGENASE 2 INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; MALE; PYRAZOLES; RATS; RATS, WISTAR; STREPTOZOCIN; SULFONAMIDES; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79958025817     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01259.2010     Document Type: Article

References (31)

1. Bakhle YS, Botting RM. Cyclooxygenase-2 and its regulation in inflammation. Mediators Inflamm 5: 305-323, 1996.
2. Chen YJ, Li J, Quilley J. Effect of inhibition of nitric oxide synthase on renal cyclooxygenase in the diabetic rat. Eur J Pharmacol 541: 80-86, 2006.
3. Chen YJ, Quilley J. Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal COX-2 expression and enhanced renal prostaglandin release. J Pharmacol Exp Ther 324: 658-663, 2008.
4. Chen YJ, Santos M, Quilley J. Treatment of diabetic rats with a peroxynitrite decomposition catalyst prevents induction of renal COX-2. Am J Physiol Heart Circ Physiol 300: H1125-H1132, 2011.
5. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 62: 929-939, 2002.
6. Davidge ST. Prostaglandin H synthase and vascular function. Circ Res 89: 650-660, 2001.
7. DiPetrillo K, Coutermarsh B, Gesek FA. Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 284: F113-F121, 2003.
8. Esmatjes E, Fernandez MR, Halperin I, Camps J, Gaya J, Arroyo V, Rivera F, Figuerola D. Renal hemodynamic abnormalities in patients with short term insulin-dependent diabetes mellitus: role of renal prostaglandins. J Clin Endocrinol Metab 60: 1231-1236, 1985.
9. Feitoza CQ, Goncalves GM, Semedo P, Cenedeze MA, Pinheiro HS, Beraldo FC, dos Santos OF, Teixeira VP, dos Reis MA, Mazzali M, Pacheco-Silva A, Camara NO. Inhibition of COX 1 and 2 prior to renal ischemia/reperfusion injury decreases the development of fibrosis. Mol Med 14: 724-730, 2008.
10. Gerrard JM, Stuart MJ, Rao GH, Steffes MW, Mauer SM, Brown DM, White JG. Alteration in the balance of prostaglandin and thromboxane synthesis in diabetic rats. J Lab Clin Med 95: 950-958, 1980.
11. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94: 2504-2510, 1994.
12. Hostetter TH. Pathogenesis of diabetic glomerulopathy: hemodynamic considerations. Semin Nephrol 10: 219-227, 1990.
13. Jensen PK, Christiansen JS, Steven K, Parving HH. Renal function in streptozotocin-diabetic rats. Diabetologia 21: 409-414, 1981.
14. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S, Adamis AP. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 16: 438-440, 2002.
15. Kalantarinia K, Awad AS, Siragy HM. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int 64: 1208-1213, 2003.
16. Komers R, Lindsley JN, Oyama TT, Anderson S. Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats. Clin Exp Pharmacol Physiol 34: 36-41, 2007.
17. Komers R, Lindsley JN, Oyama TT, Schutzer WE, Reed JF, Mader SL, Anderson S. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 107: 889-898, 2001.
18. Li J, Chen YJ, Quilley J. Effect of tempol on renal cyclooxygenase expression and activity in experimental diabetes in the rat. J Pharmacol Exp Ther 314: 818-824, 2005.
19. Makino H, Tanaka I, Mukoyama M, Sugawara A, Mori K, Muro S, Suganami T, Yahata K, Ishibashi R, Ohuchida S, Maruyama T, Narumiya S, Nakao K. Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist. J Am Soc Nephrol 13:1757-1765, 2002.
20. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96: 272-277, 1999.
21. Moel DI, Safirstein RL, McEvoy RC, Hsueh W. Effect of aspirin on experimental diabetic nephropathy. J Lab Clin Med 110: 300-307, 1987.
22. Mogensen CE, Steffes MW, Deckert T, Christiansen JS. Functional and morphological renal manifestations in diabetes mellitus. Diabetologia 21: 89-93, 1981.
23. Nasrallah R, Robertson SJ, Hebert RL. Chronic COX inhibition reduces diabetes-induced hyperfiltration, proteinuria, and renal pathological markers in 36-week B6-Ins2 (Akita) mice. Am J Nephrol 30: 346-353, 2009.
24. Quilley J, Chen YJ. Role of COX-2 in the enhanced vasoconstrictor effect of arachidonic acid in the diabetic rat kidney. Hypertension 42: 837-843, 2003.
25. Quilley J, McGiff JC, Nasjletti A. Role of endoperoxides in arachidonic acid-induced vasoconstriction in the isolated perfused kidney of the rat. Br J Pharmacol 96: 111-116, 1989.
26. Russo LM, del RE, Brown D, Lin HY. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor. Diabetes 56: 380-388, 2007.
27. Schambelan M, Blake S, Sraer J, Bens M, Nivez MP, Wahbe F. Increased prostaglandin production by glomeruli isolated from rats with streptozotocin-induced diabetes mellitus. J Clin Invest 75: 404-412, 1985.
28. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45: 522-530, 1996.
29. Sharma K, Ziyadeh FN. Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol Renal Fluid Electrolyte Physiol 267: F1094-F1101, 1994.
30. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90: 1814-1818, 1993.
31. Yong LC, Bleasel AF. Pathological changes in streptozotocin induced diabetes mellitus in the rat. Exp Pathol 30: 97-107, 1986.